Senators Demand Pricing Details On $1,000-Per-Pill Sovaldi
Two U.S. senators on Friday asked biopharmaceutical company Gilead Sciences Inc. for more information on how it prices its hepatitis C medication Sovaldi, which has become a lightning rod for criticism...To view the full article, register now.
Already a subscriber? Click here to view full article